[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthropathy":235},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,76,103,129,151,182,210],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100636293",false,"NCT07563803","The restor3d Outcomes Registry","The restor3d Outcomes Registry: Tracking Patient Recovery After Joint Replacement","Master Protocol Inclusion Criteria:\n\n* Age ≥ 18 years\n* Prescribed an FDA-cleared or approved orthopedic implant manufactured by restor3d, Inc.\n\nMaster Protocol Exclusion Criteria:\n\n* Patient is receiving an implant not manufactured by restor3d\n* Patient is receiving a restor3d implant that is not FDA-cleared or approved\n* Patient lives outside the United States\n* Patient is receiving a restor3d implant that does not use a patient-specific plan, instrumentation or implant\n* Patient is non-English-speaking\n* Patient is receiving a restor3d implant outside of the defined implant cohorts\n* Patient does not provide informed consent\n* Plus additional cohort-specific exclusion criteria","ALL","18 Years",{"count":18,"type":19},2000,"ESTIMATED","5 Years","OBSERVATIONAL","The restor3d Outcomes Registry is a prospective, longitudinal, decentralized study designed to capture patient-reported outcomes (PROs) from adults who have received an FDA-cleared or approved restor3d patient-specific orthopedic implant. Using a master protocol framework, the study enrolls patients across multiple joint cohorts (knee, hip, foot \\& ankle, shoulder) under a single protocol, with joint-specific details governed by individual appendices. Participants self-enroll and complete electronic PRO surveys (ePROs) before surgery and at 6 weeks, 3 months, 6 months, and annually through 5 years post-operatively, all remotely, with no required in-person visits. The study aims to quantify changes in pain, function, quality of life, and satisfaction over time, and to establish real-world outcome benchmarks for patient-specific orthopedic implants.",[24,25],"Joint Replacement","Arthropathy",[27,28,29,30,31],"Knee arthroplasty","Hip arthroplasty","Ankle arthroplasty","Shoulder arthroplasty","restor3d","NOT_YET_RECRUITING","2026-04-30",{"date":35,"type":36},"2026-05-04","ACTUAL",{"date":38,"type":19},"2026-05-31",{"date":40,"type":19},"2032-05-31",{"name":42,"class":43},"Restor3D","INDUSTRY",{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100635483","NCT07553273","Vibratory Anesthesia on Pain Following Corticosteroid Injections","The Effect of Vibratory Anesthesia on Patient Pain Perception in Corticosteroid Injections of the Upper Extremity","Inclusion Criteria:\n\n* Any patient of the Principal Investigator who has clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow where treatment with corticosteroid injection is indicated.\n* Participants who voluntarily consent to participate in the study and sign consent forms.\n* Participants who complete all numeric pain rating scales\n* Patients aged ≥ 18 years old\n\nExclusion Criteria:\n\n* Participants who opt out of the study or withdraw consent\n* Participants who are determined to be without capacity to consent to study participation or injection procedure by principal investigator\n* Participants with inability to complete numeric pain rating scales\n* Participants with known allergies to triamcinolone acetonide, lidocaine, or bupivicaine\n* Participants without clinically diagnosed bilateral arthritis, tendinopathy, arthropathy, or compression neuropathy of the hand, wrist, or elbow.\n* Participants where treatment with corticosteroid injection is not indicated bilaterally.\n* Patients ≤ 18 years old",{"count":51,"type":19},165,"INTERVENTIONAL",[54],"NA","This research study aims to evaluate injectional pain at the site of needle insertion for corticosteroid injections (CSI) of the upper extremity depending on different modes of anesthetics. Each individual's perception of pain upon receiving a CSI with two out of three modes of anesthesia (control\u002Fno anesthesia, vibrational anesthesia, vapo-coolant anesthesia) will be utilized to compare these variables and determine the method that is associated with the least pain.",[57,58,25,59,60],"Bilateral Arthritis of Wrist","Tendinopathy","Compression Neuropathy","Bilateral Arthritis of Hands",[62,63,64],"Pain in Hand","Pain in Elbow","Pain in Wrist","RECRUITING","2026-04-27",{"date":35,"type":36},{"date":69,"type":19},"2026-04",{"date":71,"type":19},"2027-04",{"name":73,"class":74},"The University of Texas Medical Branch, Galveston","OTHER",1,{"id":77,"slug":4,"hasResults":10,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":10,"sex":15,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":52,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":75},"100629746","NCT07478679","Radiation to Treat Joint Damage Caused by Cancer Immunotherapy","Use of Low-Dose RADiotherapy in the Management of Immune Checkpoint- Inhibitor-ArThropathy as an Immune-Related Adverse Event (RADIATE)","Inclusion Criteria:\n\n* Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which they are receiving single agent or combination immunotherapy or within the last 6 months.\n* Rheumatologist-established diagnosis of new onset CTCAE grade 2-3 immunotherapy-induced inflammatory arthritis or activated osteoarthritis, involving one or more joints (up to 3) including but not limited to hands, shoulders, elbows, hips, knees and ankles.\n* Age ≥ 40 years.\n* ECOG performance status ≤2 (Karnofsky ≥60%).\n* Patients with ability and willingness to sign consent.\n\nExclusion Criteria:\n\n* Contraindications to radiation treatment, such as pregnancy, breast-feeding women and active collagen-vascular disease.\n* Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \\>1 year prior to consent and\u002For clear documentation states that the patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment.\n* Have not received systemic steroids within the last 3 months for the treatment of immune related adverse events.\n* History of prior autoimmune conditions, or concurrent immune related adverse events requiring systemic immunosuppressants.\n* Estimated life expectancy less than 3 months as assessed by investigators.\n* Any condition at the discretion of investigator that will preclude participation in the study.\n* History of secondary malignancy as assessed by investigators.\n* History of radiation to affected joints as assessed by investigators.","40 Years",{"count":84,"type":19},20,[86],"PHASE1","This study will prospectively investigate the feasibility and safety of administering LDRT in patients with immunotherapy-induced inflammatory arthritis.",[89,25],"Arthritis",[91,25,92,93],"Radiotherapy","Immunotherapy","Cancet","2026-03-18",{"date":96,"type":36},"2026-03-23",{"date":98,"type":19},"2026-08-26",{"date":100,"type":19},"2028-09-17",{"name":102,"class":74},"University of Chicago",{"id":104,"slug":4,"hasResults":10,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100628962","NCT07468461","CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome","Profiling Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome: A Multicenter European Study","CACP","Inclusion Criteria:\n\n* Patients with clinical diagnosis and genetic confirmation of CACP syndrome.\n* Patients diagnosed during pediatric age (\\\u003C18 years).\n* Time frame: Patients diagnosed with CACP between January 2005 and January 1, 2026.\n* Informed consent obtained from parents or legal guardians.\n\nExclusion Criteria:\n\n* Patients without genetic confirmation of the diagnosis.\n* Lack of informed consent from parents or legal guardians.\n* Patients diagnosed before January 1, 2005, or after January 1, 2026.",{"count":111,"type":19},15,"CACP syndrome is a rare autosomal recessive disorder characterized by the triad of camptodactyly, non-inflammatory arthropathy with synovial hyperplasia, and coxa vara. Occasionally, non-inflammatory pericarditis and pleural effusion may also occur. This syndrome is likely underdiagnosed due to its rarity. Epidemiological information is limited to isolated case reports or small patient series, with the largest reported cohort including 35 patients.\n\nThe genetic cause of CACP syndrome is associated with mutations in the PRG4 gene, located on chromosome 1q31.1. While clinical signs (camptodactyly, non-inflammatory arthropathy, and coxa vara) and radiological findings suggest the diagnosis, genetic testing confirms it by identifying pathogenic biallelic mutations in PRG4.\n\nTo date, twenty-two mutations have been identified, all leading to premature stop codons and the absence of functional lubricin. However, the exact pathophysiology of CACP syndrome remains incompletely understood.\n\nClinical manifestations of CACP syndrome can vary, even within the same family. The progressive and slow onset can initially present as an incomplete clinical picture. However, camptodactyly (85- 100%) and arthropathy (100%) are constant features.\n\nAlthough genetically homogeneous, CACP exhibits significant intra- and interfamilial phenotypic variability due to secondary genetic factors, environmental modifiers, and complex molecular mechanisms.\n\nCamptodactyly is symmetrical, with variable distribution. It may affect fingers or toes and can be congenital or develop during childhood.\n\nArthropathy is symmetrical, primarily involving large joints (wrists, knees, ankles, elbows, and hips).\n\nCoxa vara is present in 50-90% of cases, is progressive, and tends to worsen with age. Spinal abnormalities such as lordosis, scoliosis, and kyphosis are possible, though the cervical spine is generally spared.\n\nThe articular manifestations of CACP syndrome may mimic juvenile idiopathic arthritis (JIA), and patients are often initially misdiagnosed and treated inappropriately.\n\nJoints appear swollen due to non-inflammatory synovial effusion and synovial thickening. They develop contractures, functional limitations, and sometimes musculoskeletal pain.\n\nNon-inflammatory pericarditis is reported in 30% of published cases, with variable clinical courses that may require surgical intervention in cases of constrictive pericarditis.\n\nThe routine pathway of assessments and follow-up for patients with CACP syndrome includes an initial detailed evaluation and regular monitoring. Following the diagnosis, which is based on clinical history, imaging studies, and genetic confirmation of PRG4 mutations, patients undergo periodic clinical visits, generally scheduled every six months. During these visits, the progression of the disease, articular symptoms (e.g., camptodactyly, mobility limitations), and possible extraarticular complications, such as pericarditis, are assessed.\n\nRadiological (e.g., X-rays, MRI) and laboratory assessments, however, can be spaced out over longer intervals compared to the schedule of clinical visits, typically every 1-2 years, unless specific indications arise. Nonetheless, these examinations may be requested based on contingent clinical needs, such as a sudden worsening of symptoms or suspicion of complications. This flexible approach helps to balance thorough disease monitoring with minimizing the burden on patients, while ensuring personalized and timely management of the condition.\n\nAt present, there is no specific pharmacological treatment for CACP. Management is primarily symptomatic and aimed at preventing joint deformities and extra-articular complications.\n\nCurrently, no experimental therapies are available for CACP syndrome, but future research could explore gene therapy, regenerative medicine, and biologics.\n\nThis study, involving pediatric and pediatric rheumatology centers across Italy and Europe, aims to collect epidemiological, clinical, and therapeutic data from a large cohort of patients. Its goals include better defining the disease's characteristics, understanding its natural history, and evaluating different therapeutic approaches and their efficacy. The study will also analyze potential genotypephenotype correlations.",[114,25,115,116],"Camptodactyly","Coxa Vara","Pericarditis",[118],"Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome","2026-03-13",{"date":121,"type":36},"2026-03-16",{"date":123,"type":36},"2025-08-01",{"date":125,"type":19},"2038-01-01",{"name":127,"class":74},"Meyer Children's Hospital IRCCS",10,{"id":130,"slug":4,"hasResults":10,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100474595","NCT05459948","The Medacta GMK SpheriKA Post-Marketing Surveillance Study","Medacta GMK® SpheriKA and Kinematic Alignment Technique Multicenter, Post-Market Outcome Study","Inclusion Criteria:\n\n* Patients willing to sign the informed consent.\n* Patients able to comply with follow-up requirements, including postoperative weight-bearing restrictions and self-evaluations.\n* Patients 18 - 80 years of age at the time of surgery.\n* Patients requiring a primary total knee replacement (on label use).\n* Patients with intact collateral ligaments.\n\nExclusion Criteria:\n\n* Patients with inflammatory arthritis.\n* Morbidly obese patients, with a body mass index (BMI) \\> 40.\n* Patients with a history of total or unicompartmental reconstruction of the affected joint.\n* Patients that have had a high tibial osteotomy or femoral osteotomy.\n* Patients with neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.\n* Patients with a systemic or metabolic disorder leading to progressive bone deterioration.\n* Patients that are immunologically compromised or receiving chronic steroids (\\> 30 days).\n* Patients whose bone stock is compromised due to disease or infection, unable to provide adequate support and\u002For fixation to the prosthesis.\n* Patients with an active or suspected latent infection in or surrounding the knee joint.\n* Pregnant or breastfeeding women.","80 Years",{"count":137,"type":19},281,"This is a Post-Marketing Surveillance of GMK SpheriKA knee stem prosthesis.",[25,140],"Knee Replacement","2025-09-23",{"date":143,"type":36},"2025-09-29",{"date":145,"type":36},"2022-07-30",{"date":147,"type":19},"2035-05",{"name":149,"class":43},"Medacta International SA",4,{"id":152,"slug":4,"hasResults":10,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":52,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":150},"100461721","NCT05292339","Ketorolac in Upper Extremity Tendinopathy and Arthropathy","Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy","Inclusion Criteria:\n\n* Age 18 or older,\n* symptomatic tendinopathy or arthropathy of the shoulder, elbow, hand, or wrist who have not undergone prior surgical treatment for their condition.\n* Diagnoses may include trigger finger, De Quervain's tenosynovitis, radiocarpal osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, or proximal interphalangeal joint osteoarthritis.\n\nExclusion Criteria:\n\n* Patients under the age of 18,\n* Patients who have undergone prior triamcinolone or ketorolac injections within the past 6 months,\n* Patients who have undergone prior surgical treatment for their hand condition,\n* Patients with allergy or contraindication to triamcinolone or ketorolac injection,\n* Patients with an active infection at the treatment site \\[active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. white blood cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)\\].",{"count":158,"type":19},160,[160],"PHASE4","Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints.\n\nThe goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy.\n\nParticipants will be blinded to the treatment received. The duration of an individual participant's participation in this study is 24 weeks. During this time period, patients will be asked to return to the clinic for an in-person follow-up 6 weeks after the injection with either ketorolac or triamcinolone) in order to assess participants' outcomes. All work related to this project will take place at the Emory Sports Medicine Complex, Emory Executive Park, Emory Musculoskeletal Institute, the Emory University Orthopaedic and Spine Hospital, and the Emory Saint Joseph's Hospital. This study will add to existing knowledge by providing further insight into how wrist arthropathy should be most optimally and conservatively managed.",[163,58,25],"Osteoarthritis",[165,166,167,168,169,170,171,172],"First Carpometacarpal Joint","Ketoralac","metacarpophalangeal joint osteoarthritis","trigger finger","De Quervain's tenosynovitis","radiocarpal osteoarthritis","Triamcinolone","Upper extremity","2025-08-19",{"date":175,"type":36},"2025-08-24",{"date":177,"type":36},"2023-01-31",{"date":179,"type":19},"2027-07",{"name":181,"class":74},"Emory University",{"id":183,"slug":4,"hasResults":10,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":10,"sex":15,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":52,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":75},"100596086","NCT07040878","Antigravity Treadmill After Joint Arthroplasty","Antigravity Treadmill Rehabilitation After Lower Limb Arthroplasty in Older Adults","Inclusion Criteria:\n\n* individuals who have recently undergone hip or knee joint arthroplasty surgeries aged 60 years and above.\n\nExclusion Criteria:\n\n* cognitive impairments that prevent independent completion of research questionnaires\n* history of consciousness disturbances, psychotic disorders, bipolar disorder, or other severe psychiatric illnesses\n* functional status preventing independent ambulation (wheelchair-bound or bedridden patients; orthopedic devices such as crutches or walker allowed)\n* refusal to participate in the study at any stage","60 Years","75 Years",{"count":191,"type":19},60,[54],"The study aims to evaluate the efficacy of antigravity treadmill training and body weight-supported treadmill training in the rehabilitation of elderly patients (60-75 years) following hip or knee arthroplasty.",[25,163],[196,197,198,199,200],"arthroplasty","balance","fall risk","gait rehabilitation","psychological outcomes","2025-06-26",{"date":203,"type":36},"2025-06-27",{"date":205,"type":36},"2025-05-15",{"date":207,"type":19},"2026-06-30",{"name":209,"class":74},"Wroclaw University of Health and Sport Sciences",{"id":211,"slug":4,"hasResults":10,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":52,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":75},"100487595","NCT05629130","Embolization in Hereditary Coagulopathies","EHCO","Inclusion Criteria:\n\n* Patients with hereditary coagulopathies with arthropathy (i.e., chronic synovitis due to hemarthrosis), with X-ray and MRI (documenting synovitis) followed up at the Hemophilia Center HC-FMUSP.\n\nExclusion Criteria:\n\n* Patients who do not complete the planned assessments\n* Patients who do not accept to continue with the study.",{"count":217,"type":19},30,[54],"This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and\u002For ankles followed up at the Centro de Hemofilia HCFMUSP, after approval by the ethics and research committee.\n\nThey will undergo imaging tests (X-rays and Magnetic Resonance of knee, elbow, or ankle), physical, pain, quality of life and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter, Test Timed up and Go, 30 second sit and stand test, Haemophilia - Adult - Quality of Life questionnaire (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score, EQ-5D, numerical rating scale for pain and embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France), until partial vascular stasis and decharacterization of pathological synovial enhancement.\n\nThese evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.",[221,222,223,224,225,25],"Hemophilia","Embolization","Hemarthrosis","Clotting Factor Deficiency","Synovitis","2022-11-16",{"date":228,"type":36},"2022-11-29",{"date":230,"type":19},"2023-01-16",{"date":232,"type":19},"2029-12-31",{"name":234,"class":74},"University of Sao Paulo General Hospital",""]